Physician profile
Sherly Jaimon
NPI 1619480480
$3,666.66
in general payments reported to CMS, 2019-2025
19 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.74 · 2022: $385 · 2023: $605 · 2024: $1,198 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,199.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $709.99 | 2022-2025 | Qelbree, Qelbree |
| Ucb, INC. | $526.66 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Corium, LLC | $503.26 | 2022-2025 | Azstarys |
| Abbvie INC. | $392.67 | 2024-2025 | |
| Neurelis, INC. | $303.30 | 2022-2025 | Valtoco |
| Collegium Pharmaceutical, INC. | $275.23 | 2025 | Jornay Pm |
| Evofem Biosciences, INC. | $177.19 | 2023-2025 | Phexxi, Solosec, Phexx |
| Ironshore Pharmaceuticals INC. | $163.12 | 2022-2024 | |
| Neos Therapeutics, LP | $148.91 | 2022-2024 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $119.24 | 2024-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $101.60 | 2024-2025 | Ultomiris |
| Tris Pharma INC | $97.57 | 2022-2025 | Dyanavel Xr |
| Sumitomo Pharma America, INC. | $27.34 | 2023 | Myfembree |
| Harmony Biosciences LLC | $25.95 | 2024 | |
| Exeltis, USA INC. | $24.59 | 2025 | Slynd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $19.78 | 2024 | Relexxii |
| Myovant Sciences INC. | $18.55 | 2022 | |
| Eisai INC. | $17.34 | 2025 | |
| Ns Pharma, INC. | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherly Jaimon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.